#0600 🔬BKZ achieves sustained impact in PsA ➡️ BE OPTIMAL & BE COMPLETE trials:BKZ 160 mg Q4W bDMARD-naïve & TNFi-IR PsA pts ➡️Pain,function,fatigue & skin showed greatest & sustained reductions @ 2 yrs👇 🎯BKZ offers sustained response in 🔑PsA domains #ACR24 @RheumNow https://t.co/uhzZoOrr3H

🌟 Join us for the Aging Strong session at #ACR24! We are thrilled to have Dr Cynthia Boyd, division director of Geriatrics at Hopkins, visit us to discuss how to manage multicomplexity in older rheumatic patients. #GeriRheum @RheumNow @cynthiaboyd16 @UnaMakris https://t.co/QZpOmdgzOR

Using #MachineLearning for predicting flares in axSpA @DiegoBenavent et al, data from METEOR-SpA registry showed the ff predictors of flares thru the reduced logistic regression model: 🔅lower ASDAS 🔅enthesitis 🔅prior flares 🔅longer treatment duration @RheumNow #ACR24 abs559 https://t.co/wyIo9gnKVJ

📈 Data from @UIowa_Rheum on how rurality impacts delay to diagnosis in #GCA 📍 0747 👉🏼 People living in more rural areas have an increased time to diagnosis & treatment- further prospective studies needed to delineate effects of rurality further @RheumNow #ACR24 @LemonReneeNi https://t.co/3YMcI9ha3T

Harkins @DrTrishHarkins et al. People with PMR exhibit an accelerated physical aging phenotype at baseline. High rates of frailty (41%), pre-frailty (28%), cognitive impairment (74%!), sarcopenia (23%), osteoporosis (21%) @RheumNow #ACR24 Abstr#0740 https://t.co/4ZT8VtGi1W https://t.co/xBQ5CLlb5A

Does apremilast have cardiometabolic benefits? Abstract 0598: In PsA patients, 1-year treatment with apremilast associated w/ ↓ body fat mass, including android fat, and was linked w/ improved disease activity (DAS28-CRP). #ACR24 @RheumNow https://t.co/11n4gQN7Xo

Characteristics of difficult-to-treat AS accdg to a retrospective study by @DaoudAnsaam @mmagrey1 et al ⬆️ BMI + comorbidities: HTN, CKD, depression + EAMs: IBD, Pso, iridocyclitis + HLA-B27 Interesting real world data. @RheumNow #ACR24 abs573 https://t.co/GlE4tFpsSz

FDA has given FDA Breakthrough Therapy designation to Nipocalimab for treatment of adults w/ moderate-to-severe Sjögren’s disease. NIPO is an Ab to neonatal Fc receptor (FcRn), & was tested and shown effective in Sjog in the Phase 2 DAHLIAS study - a plenary presentation at… https://t.co/aQDp7iPKXD https://t.co/hJ8fe6JwxC

Puechal et al. Serial ANCA testing may predict relapse in a large group of AAV patients but is NOT useful for individual patients. @RheumNow #ACR24 Abstr#0721 https://t.co/ClvTk2Tlar https://t.co/k4vc7l9jzK

#0589 🔬Time to Response in PsA Domains: Secukinumab ➡️Post-hoc analyses, n=1366 🔑Median time (wks) to MCID 👇 🔴Systemic inflammation <2 🔴MSK: ~4 wks (enthesitis~12) 🔴Fatigue~7–8 🔴PASI75~8–12; nails ~24 🩺 Rapid MSK & QoL benefits precede skin/nail #ACR24 @RheumNow https://t.co/WfqkryA1CC